About: ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.00 (+1.51%)
ABVC NASDAQ ABVC Biopharma Inc
ABVC Biopharma Inc share price
ABVC price activity
Last Price
$1.000
Change (24hr)
0.01 USD (1.51%)
Volume
42.56K
Volume (4w avg)
-
Open
$1.02
Day Range
$0.96 - $1.02
Previous Close
$0.99
Last Trade
04 Nov, 9:00 pm GMT+0
Delayed
04 Nov, 9:00 pm GMT+0
ABVC price performance
Delayed
04 Nov, 9:00 pm GMT+0
ABVC details
ABVC Market Signals